atenolol has been researched along with pyrroles in 14 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (14.29) | 18.2507 |
| 2000's | 9 (64.29) | 29.6817 |
| 2010's | 3 (21.43) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Donnelly, R; Elliott, HL; Meredith, PA; Reid, JL | 1 |
| Satake, N; Shibata, M; Shibata, S | 1 |
| Bruijnzeel, A; Croiset, G; de Wied, D; Diamant, M; Nijsen, MJ; Stam, R; Wiegant, VM | 1 |
| Liebson, PR | 1 |
| Khadipash, LA; Kiseleva, NV; Kosmatova, OV; Mamedov, MN; Oganov, RG; Perova, NV | 1 |
| Kumar, V; Shah, RP; Singh, S | 1 |
| Mehlsen, J | 1 |
| Chang, CL; Dahlof, B; Mastorantonakis, S; Poulter, NR; Sever, PS; Wedel, H | 1 |
| Dahlof, B; Poulter, NR; Sever, PS; Wedel, H | 1 |
| Buxton, M; Dahlöf, B; Jönsson, B; Kahan, T; Lindgren, P; Poulter, NR; Sever, PS; Wedel, H | 1 |
| Chattopadhyay, S; Dey, S; Mazumder, B | 1 |
| Brown, I; Gallivan, C | 1 |
| El-Zohairy, SN; Ezeamuzie, CI; Oriowo, MA | 1 |
2 trial(s) available for atenolol and pyrroles
| Article | Year |
|---|---|
LIFE and ARBITER.
Topics: Adrenergic beta-Antagonists; Antihypertensive Agents; Atenolol; Atorvastatin; Carotid Artery Diseases; Cholesterol, LDL; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertension; Hypertrophy, Left Ventricular; Losartan; Pravastatin; Pyrroles; Treatment Outcome | 2003 |
Coronary heart disease benefits from blood pressure and lipid-lowering.
Topics: Amlodipine; Anticholesteremic Agents; Antihypertensive Agents; Atenolol; Atorvastatin; Blood Pressure; Coronary Disease; Heptanoic Acids; Humans; Hypertension; Perindopril; Pyrroles; Risk Factors; Risk Reduction Behavior; Sodium Chloride Symporter Inhibitors | 2009 |
12 other study(ies) available for atenolol and pyrroles
| Article | Year |
|---|---|
Clinical studies with the potassium channel activator cromakalim in normotensive and hypertensive subjects.
Topics: Adult; Antihypertensive Agents; Atenolol; Benzopyrans; Blood Pressure; Cromakalim; Heart Rate; Humans; Hypertension; Kidney; Liver Circulation; Lung; Male; Potassium Channels; Pyrroles; Renin | 1990 |
The inhibitory effects of iberiotoxin and 4-aminopyridine on the relaxation induced by beta 1- and beta 2-adrenoceptor activation in rat aortic rings.
Topics: 4-Aminopyridine; Adrenergic beta-Agonists; Adrenergic beta-Antagonists; Analysis of Variance; Animals; Aorta, Thoracic; Atenolol; Carbazoles; Cyclic AMP; Cyclic AMP-Dependent Protein Kinases; Dose-Response Relationship, Drug; Imines; Indoles; Isoproterenol; Male; Muscle Relaxation; Muscle, Smooth, Vascular; Peptides; Propanolamines; Pyrroles; Rats; Scorpion Venoms | 1996 |
The role of the CRH type 1 receptor in autonomic responses to corticotropin- releasing hormone in the rat.
Topics: Adrenergic beta-Antagonists; Animals; Atenolol; Autonomic Nervous System; Corticotropin-Releasing Hormone; Heart Rate; Male; Motor Activity; Neurosecretory Systems; Pyrimidines; Pyrroles; Rats; Rats, Wistar; Receptors, Corticotropin-Releasing Hormone | 2000 |
[Effect of combined antihypertensive and lipid lowering therapy on the level of coronary risk and tissue insulin resistance in patients with metabolic syndrome].
Topics: Adult; Antihypertensive Agents; Atenolol; Atorvastatin; Blood Pressure; Cholesterol, HDL; Cholesterol, LDL; Drug Therapy, Combination; Female; Fenofibrate; Heptanoic Acids; Humans; Hypolipidemic Agents; Indapamide; Male; Metabolic Syndrome; Middle Aged; Perindopril; Pyrroles; Simvastatin; Treatment Outcome | 2003 |
[ASCOT-BPLA Study raises new questions regarding: which is the best initial antihypertensive drug?].
Topics: Adrenergic beta-Antagonists; Amlodipine; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Atenolol; Atorvastatin; Calcium Channel Blockers; Cardiovascular Diseases; Doxazosin; Drug Therapy, Combination; Follow-Up Studies; Heptanoic Acids; Humans; Hypertension; Perindopril; Pyrroles; Sodium Chloride Symporter Inhibitors; Treatment Outcome | 2005 |
LC and LC-MS methods for the investigation of polypills for the treatment of cardiovascular diseases. Part 1. Separation of active components and classification of their interaction/degradation products.
Topics: Aspirin; Atenolol; Atorvastatin; Cardiovascular Agents; Chromatography, High Pressure Liquid; Drug Combinations; Drug Interactions; Drug Stability; Heptanoic Acids; Hydrochlorothiazide; Lisinopril; Pravastatin; Pyrroles; Simvastatin; Spectrometry, Mass, Electrospray Ionization | 2008 |
[Hypertension--does it matter how blood pressure is lowered?].
Topics: Amlodipine; Anticholesteremic Agents; Antihypertensive Agents; Atenolol; Atorvastatin; Bendroflumethiazide; Cardiovascular Diseases; Cost-Benefit Analysis; Diuretics; Drug Administration Schedule; Drug Therapy, Combination; Evidence-Based Medicine; Heptanoic Acids; Humans; Hypertension; Perindopril; Pyrroles; Treatment Outcome | 2008 |
Antihypertensive therapy and the benefits of atorvastatin in the Anglo-Scandinavian Cardiac Outcomes Trial: lipid-lowering arm extension.
Topics: Anticholesteremic Agents; Antihypertensive Agents; Atenolol; Atorvastatin; Cholesterol; Chronic Disease; Coronary Disease; Epidemiologic Methods; Female; Follow-Up Studies; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertension; Male; Middle Aged; Pyrroles; Randomized Controlled Trials as Topic; Stroke; Time Factors; Treatment Outcome | 2009 |
The lifetime cost effectiveness of amlodipine-based therapy plus atorvastatin compared with atenolol plus atorvastatin, amlodipine-based therapy alone and atenolol-based therapy alone: results from ASCOT1.
Topics: Adrenergic beta-Antagonists; Amlodipine; Antihypertensive Agents; Atenolol; Atorvastatin; Calcium Channel Blockers; Cardiovascular Diseases; Cost-Benefit Analysis; Drug Therapy, Combination; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertension; Models, Economic; Pyrroles; Scandinavian and Nordic Countries; Treatment Outcome | 2009 |
Formulation and evaluation of fixed-dose combination of bilayer gastroretentive matrix tablet containing atorvastatin as fast-release and atenolol as sustained-release.
Topics: Administration, Oral; Atenolol; Atorvastatin; Chemistry, Pharmaceutical; Delayed-Action Preparations; Drug Combinations; Heptanoic Acids; Humans; Hypercholesterolemia; Hypertension; Pyrroles; Solubility | 2014 |
Olmesartan induced enterocolitis.
Topics: Aged; Amitriptyline; Anticholesteremic Agents; Antidepressive Agents, Tricyclic; Antihypertensive Agents; Atenolol; Atorvastatin; Dihydropyridines; Enterocolitis; Female; Heptanoic Acids; Humans; Imidazoles; Pyrroles; Tetrazoles | 2014 |
Cyclic Adenosine Monophosphate-Mediated Enhancement of Vascular Endothelial Growth Factor Released by Differentiated Human Monocytic Cells: The Role of Protein Kinase A.
Topics: Adrenergic Antagonists; Adrenergic beta-Agonists; Albuterol; Atenolol; Carbazoles; Cyclic AMP; Cyclic AMP-Dependent Protein Kinases; Dose-Response Relationship, Drug; Ethanolamines; Humans; Isoproterenol; Lipopolysaccharides; Macrophages; Procaterol; Pyrroles; Vascular Endothelial Growth Factor A | 2015 |